CohBar, Inc. Stock

Equities

CWBR

US19249J3077

Biotechnology & Medical Research

Market Closed - OTC Markets 01:58:22 2024-05-16 pm EDT 5-day change 1st Jan Change
0.88 USD +15.77% Intraday chart for CohBar, Inc. +15.77% +18.92%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 4.93M
Net income 2021 -15M Net income 2022 -12M EV / Sales 2021 -
Net cash position 2021 25.88M Net cash position 2022 15.74M EV / Sales 2022 -
P/E ratio 2021
-1.51 x
P/E ratio 2022
-0.4 x
Employees 10
Yield 2021 *
-
Yield 2022
-
Free-Float 84.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day+15.77%
1 week+15.77%
Current month+2.33%
1 month-2.25%
3 months+15.79%
6 months-0.01%
Current year+18.92%
More quotes
1 week
0.76
Extreme 0.7601
1.00
1 month
0.51
Extreme 0.5103
1.00
Current year
0.51
Extreme 0.5103
1.01
1 year
0.51
Extreme 0.5103
6.90
3 years
0.51
Extreme 0.5103
68.10
5 years
0.51
Extreme 0.5103
127.50
10 years
0.51
Extreme 0.5103
323.67
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 22-01-03
Members of the board TitleAgeSince
Director/Board Member 63 Nov. 05
More insiders
Date Price Change Volume
24-05-16 0.88 +15.77% 954
24-05-15 0.7601 -23.98% 840
24-05-13 0.9999 +31.55% 931

Delayed Quote OTC Markets, May 16, 2024 at 01:58 pm EDT

More quotes
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW